Edwin M Horwitz
Overview
Explore the profile of Edwin M Horwitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
2878
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Burnham A, Foppiani E, Horwitz E
Front Immunol
. 2020 Dec;
11:609277.
PMID: 33365034
Mesenchymal stromal cells (MSCs) are spindle-shaped, plastic-adherent cells with potent immunosuppressive activity both and . MSCs have been employed as a cellular immunotherapy in diverse preclinical models and clinical trials,...
12.
Burnham A, Daley-Bauer L, Horwitz E
Blood Adv
. 2020 Nov;
4(22):5877-5887.
PMID: 33232479
Mesenchymal stromal cells (MSCs) are widely recognized to possess potent immunomodulatory activity, as well as to stimulate repair and regeneration of diseased or damaged tissue. These fundamental properties suggest important...
13.
Chilmonczyk M, Doron G, Kottke P, Culberson A, Leguineche K, Guldberg R, et al.
Biotechnol J
. 2020 Sep;
16(3):e2000277.
PMID: 32975016
Nascent advanced therapies, including regenerative medicine and cell and gene therapies, rely on the production of cells in bioreactors that are highly heterogeneous in both space and time. Unfortunately, advanced...
14.
Mastrolia I, Foppiani E, Murgia A, Candini O, Samarelli A, Grisendi G, et al.
Stem Cells Transl Med
. 2019 Jul;
8(11):1135-1148.
PMID: 31313507
Identified 50 years ago, mesenchymal stromal/stem cells (MSCs) immediately generated a substantial interest among the scientific community because of their differentiation plasticity and hematopoietic supportive function. Early investigations provided evidence...
15.
Foppiani E, Candini O, Mastrolia I, Murgia A, Grisendi G, Samarelli A, et al.
Stem Cell Res Ther
. 2019 Mar;
10(1):101.
PMID: 30890185
Background: The ex vivo expansion potential of mesenchymal stromal/stem cells (MSC) together with their differentiation and secretion properties makes these cells an attractive tool for transplantation and tissue engineering. Although...
16.
Rossignoli F, Spano C, Grisendi G, Foppiani E, Golinelli G, Mastrolia I, et al.
Theranostics
. 2019 Feb;
9(2):436-448.
PMID: 30809285
Pancreatic cancer is the fourth leading cause of cancer death in western countries with more than 100,000 new cases per year in Europe and a mortality rate higher than 90%....
17.
Spano C, Grisendi G, Golinelli G, Rossignoli F, Prapa M, Bestagno M, et al.
Sci Rep
. 2019 Feb;
9(1):1788.
PMID: 30742129
Pancreatic ductal adenocarcinoma (PDAC) is still one of the most aggressive adult cancers with an unacceptable prognosis. For this reason novel therapies accounting for PDAC peculiarities, such as the relevant...
18.
Golinelli G, Grisendi G, Prapa M, Bestagno M, Spano C, Rossignoli F, et al.
Cancer Gene Ther
. 2018 Nov;
27(7-8):558-570.
PMID: 30464207
Tumor targeting by genetically modified mesenchymal stromal/stem cells (MSCs) carrying anti-cancer molecules represents a promising cell-based strategy. We previously showed that the pro-apoptotic agent tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)...
19.
Rossignoli F, Grisendi G, Spano C, Golinelli G, Recchia A, Rovesti G, et al.
Cancer Gene Ther
. 2018 Jun;
26(1-2):11-16.
PMID: 29955091
Cellular therapies based on mesenchymal stromal/stem cells (MSC) are promising strategies in regenerative medicine and oncology. Despite encouraging results, there is still some level of concerns on inoculating MSC in...
20.
Relation T, Yi T, Guess A, La Perle K, Otsuru S, Hasgur S, et al.
Stem Cells
. 2018 Feb;
36(6):915-924.
PMID: 29430789
Neuroblastoma, the most common extracranial solid tumor in childhood, remains a therapeutic challenge. However, one promising patient treatment strategy is the delivery of anti-tumor therapeutic agents via mesenchymal stromal cell...